Provided by Tiger Trade Technology Pte. Ltd.

Revolution Medicines, Inc.

209.46
-2.2750-1.07%
Post-market: 209.500.0400+0.02%19:50 EDT
Volume:2.12M
Turnover:444.42M
Market Cap:44.89B
PE:-23.48
High:212.74
Open:212.06
Low:206.75
Close:211.74
52wk High:220.34
52wk Low:35.62
Shares:214.34M
Float Shares:184.00M
Volume Ratio:1.37
T/O Rate:1.15%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-8.9212
EPS(LYR):-5.9502
ROE:-79.09%
ROA:-30.12%
PB:17.23
PE(LYR):-35.20

Loading ...

Analysts’ Top Healthcare Picks: Revolution Medicines (RVMD), Apogee Therapeutics (APGE)

TIPRANKS
·
Jun 29

U.S. Research Roundup-3m Co, Nike, Primoris Services

Reuters
·
Jun 29

Revolution Medicines CFO Jack Anders Reports $3.35 Million Common Stock Disposal

Reuters
·
Jun 27

This Biotech ETF Has Almost Doubled in 13 Months. Money is Flowing In.

Dow Jones
·
Jun 27

Revolution Medicines Faces 'Uphill Battle' in Potential Patent Claim Against Erasca, RBC Says

MT Newswires Live
·
Jun 26

Movement Alert|Revolution Medicines Rises 5.91% in Regular Trading, Rasolute 305 Phase 3 Trial Dosing Initiated and UBS Highlights 40% Revenue Upside

Market Focus
·
Jun 25

Bank of America Securities Sticks to Its Buy Rating for Revolution Medicines (RVMD)

TIPRANKS
·
Jun 25

Analysts Offer Insights on Healthcare Companies: Aquestive Therapeutics (AQST), Revolution Medicines (RVMD) and Bolt Biotherapeutics (BOLT)

TIPRANKS
·
Jun 25

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Jun 25

Revolution Medicines to Present Phase 1/2 Zoldonrasib-chemo Data in First-line KRAS G12D Metastatic Pancreatic Cancer at ESMO GI 2026

Reuters
·
Jun 25

Revolution Medicines begins treating patients in RASolute 305 trial

TIPRANKS
·
Jun 24

Analysts Are Bullish on These Healthcare Stocks: Revolution Medicines (RVMD), Praxis Precision Medicines (PRAX)

TIPRANKS
·
Jun 23

Revolution Medicines starts Phase 3 RASolute 305 trial of zoldonrasib plus chemotherapy in first-line metastatic RAS G12D pancreatic cancer

Reuters
·
Jun 23

Revolution Medicines Begins Treating Patients in Rasolute 305, a Phase 3 Clinical Trial Evaluating Zoldonrasib in Combination With Chemotherapy as a First Line Treatment for Patients With Ras G12d Metastatic Pancreatic Cancer

THOMSON REUTERS
·
Jun 23

Revolution Medicines' PDAC Revenue Could Rise Up to 40% on Positive Doublet Data, UBS Says

MT Newswires Live
·
Jun 22

Revolution Medicines R&D chief Steve Kelsey to step down as senior adviser July 1

Reuters
·
Jun 22

Revolution Medicines shareholders ratify PwC as auditor for fiscal 2026

Reuters
·
Jun 22

Revolution Medicines Announces Planned Leadership Transition for Steve Kelsey, M.d.

THOMSON REUTERS
·
Jun 22

MEDIA-Cancer drugmaker Revolution Medicines says sale not a priority - FT

Reuters
·
Jun 21

Revolution Medicines COO Margaret Horn disposes of 93,575 common shares worth $14.99 million

Reuters
·
Jun 18